Emergent BioSolutions reports Q1 adjusted EPS 71c, consensus 70c

Reports Q1 revenue $222.2M, consensus $219M. “Over the past 12 months, we have been executing our multi-year strategic plan to stabilize the company, streamlining operations with an eye toward driving profitability and transforming the company to achieve long-term, sustainable growth built on Emergent’s strengths and unique capabilities,” said Joe Papa, president and CEO of Emergent. “We believe our solid first-quarter results are marked by revenues within our guidance range, overall increased profitability margins, increased cash on hand and improved cash flow, further demonstrating that our disciplined approach is setting the momentum for our continued turnaround actions this year. We remain confident in our 2025 financial guidance and anticipate delivering a strong second half of the year.”